One donor – multiple recipients
MedXCell NKar pipeline comprises an ongoing preclinical proof of concept program (24 months) focused in two hematological cancer.
The next step will address solid cancer and autoimmune cells.
Natural killer (NK) cells are bone marrow-derived cytotoxic lymphocytes that can destroy target cells without the need for prior antigen stimulation. NK can provide a potential source of allogeneic “off-the-shelf” cellular therapy, mediating significant anti-target effects without inducing potentially lethal side effects.
MedXCell NKar technology, named NKab, allows to stably load NK cells with antibodies targeting specific antigens with no need for any NK cell genetic modifications. Thus, providing antigenic specificity and discrete targeting to innate killer cells. Such technology can lead to a safe, affordable and effective therapy against several diseases and most tumors.